Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
4 hedge funds and large institutions have $335K invested in Biostar Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
520% more capital invested
Capital invested by funds: $54K → $335K (+$281K)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$271K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.13K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| $331K | +$271K | +85,628 | +550% |
|
|
2
UBS Group
Zurich,
Switzerland
| $3K | +$2.13K | +672 | +214% |
|
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1K | +$1.26K | +399 | +39,900% |
|
|
VF
4
Virtu Financial
New York
| – | -$25K | -14,186 | Closed |
|
BSPM Hedge Fund Activity: Q1 2018 in Review
4 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q1 2018, worth a combined $335K — up 520% from $54K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BSPM and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was Acadian Asset Management, adding an estimated $271K. The largest seller was Virtu Financial, exiting entirely with an estimated $25K sold.
- 4 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q1 2018, down from 5 in Q4 2017.
- Funds reported $335K of Biostar Pharmaceuticals, Inc. stock for Q1 2018, up 520% quarter-over-quarter.
- 0 funds opened new Biostar Pharmaceuticals, Inc. positions in Q1 2018 and 1 closed out, a net change of -1 holder.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q1 2018 was Acadian Asset Management, an estimated $271K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q1 2018 was Virtu Financial, an estimated $25K sold.
Based on aggregated 13F filings for Q1 2018.